FDA RECALLS & COURT ACTIONS: Nov. 10, 1993
Executive Summary
CLASS II -- ATENOLOL WITH CHLORTHALIDONE TABLETS 50 mg/25 mg, Rx used as a combination antihypertensive/diuretic, packaged in bottles of 100. Recall number D-018-4. Lot numbers: 25322 EXP July 1995 (Rugby & Mutual), 25323 EXP July 1995 (Mutual, URL & Geneva), 25324 EXP July 1995 (URL, Goldline, Mutual). Manufacturer: Mutual Pharmaceutical Company, Inc., Philadelphia, Pennsylvania. Recalled by: Manufacturer, by letter Sept. 15, 1993. Firm-initiated recall complete. Distribution: Nationwide; Lot number 25322 -- 1,662 bottles (Rugby), 1,675 bottles (Mutual); Lot number 25323 -- 352 bottles (Mutual), 144 bottles (URL), 4,320 bottles (Geneva); Lot number 25324 -- 288 bottles (URL), 49 bottles (Goldline), 809 bottles (Mutual). Reason: Product does not meet disintegration specifications. CLASS II -- CORTISONE ACETATE TABLETS, USP 10 mg and 25 mg, in bottles of 100, used as replacement therapy in adrenocortical deficiency states: Recall number D-021/022-4. Lot numbers: 982DF, 733HS (10 mg); 561FD, 616HJ, 535DW (25 mg). Manufacturer: The Upjohn Company, Kalamazoo, Michigan. Recalled by: Manufacturer, by letters Dec. 4, 1992 and Nov. 8, 1993. Firm- initiated recall ongoing. Distribution: Nationwide and international; 29,790 bottles of lot numbers 982DF, 733HS, 561FD and 616HJ and 14,539 bottles of lot numbers 535DW were distributed. Reason: Product does not meet dissolution specifications through expiration date. CLASS II -- LACRISERT A sterile Rx 5 mg Hydroxypropyl Cellulose Ophthalmic Insert and Applicator, indicated in patients with moderate to severe dry eye syndromes. Recall number: D-020-4. Lot number W0213. Manufacturer: Merck Manufacturing Division, Division of Merck & Company, Inc., West Point, Pennsylvania. Recalled by: Manufacturer, by letters beginning Nov. 4, 1993. Firm-initiated recall ongoing. Distribution: Nationwide and international; 4,077 units were distributed; firm estimates that very little if any of the product remains on the market. Reason: Lack of assurance of sterility.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth